- Home
- CTO vs ALLO Comparison
CTO vs ALLO Comparison
Compare CTO & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTO | ALLO |
|---|---|---|
| Founded | 1902 | 2017 |
| Country | United States | United States |
| Employees | 42 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 695.9M | 707.6M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | CTO | ALLO |
|---|---|---|
| Price | $22.16 | $1.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 15 |
| Target Price | ★ $22.50 | $8.35 |
| AVG Volume (30 Days) | 323.0K | ★ 8.4M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 7.44% | N/A |
| EPS Growth | N/A | ★ 34.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.63 | N/A |
| Revenue Next Year | $2.76 | $142,416.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.07 | $0.99 |
| 52 Week High | $22.66 | $4.46 |
Technical Indicators
Market Signals| Indicator | CTO | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 60.41 | 38.03 |
| Support Level | $17.79 | $1.56 |
| Resistance Level | $22.66 | $1.92 |
| Average True Range (ATR) | 0.40 | 0.11 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 73.14 | 7.23 |
Price Performance
Historical ComparisonAbout CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties in diversified markets in the United States. The company operates in four primary business segments: Income properties, management services, commercial loans and investments, and real estate operations. It derives maximum revenue from Income Properties.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).